Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: Observations from the SAVOR-TIMI 53 Trial

JAMA Cardiology

Volumn 3, Issue 2, 2018, Pages 155-163

  Scirica, Benjamin M ^a   Mosenzon, Ofri ^b   Bhatt, Deepak L ^a   Udell, Jacob A ^c,d   Steg, Ph Gabriel ^e,f   McGuire, Darren K ^g   Im, Kyungah ^a   Kanevsky, Estella ^a   Stahre, Christina ^h   Sjöstrand, Mikaela ^h   Raz, Itamar ^b   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e BICHAT HOSPITAL   (France)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CREATININE; PLACEBO; SAXAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN;

ADULT; AGED; ALBUMINURIA; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC VALUE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPLICATION; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; PHYSIOLOGY; URINE;

ADAMANTANE; ALBUMINURIA; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HOSPITALIZATION; HUMANS; INCRETINS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 85043519644     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.4228     Document Type: Article

References (39)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ,Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532-2539.
2. Kidney Disease Improving Global Outcomes (KDIGO) CKDWork Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. http://www.kdigo.org/clinical-practice-guidelines/pdf/CKD/KDIGO-2012-CKD-GL.pdf. Published January 2013. Accessed September 28, 2017.
3. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: A systematic review. JAMA. 2015;313(8): 837-846.
4. Molitch ME, Adler AI, Flyvbjerg A, et al. Diabetic kidney disease: A clinical update from Kidney Disease: Improving global outcomes. Kidney Int. 2015;87(1):20-30.
5. American Diabetes Association. Microvascular complications and foot care. Diabetes Care. 2016; 39(suppl 1):S72-S80.
6. Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-426.
7. Fox CS, Matsushita K,Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: Ameta-analysis. Lancet. 2012;380(9854):1662-1673.
8. Tonelli M, Muntner P, Lloyd A, et al; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet. 2012;380(9844):807-814.
9. Matsushita K, Coresh J, Sang Y, et al; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514-525.
10. Preiss D, Thomas LE, Sun JL, et al. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: An observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open. 2012;2(6):e001925.
11. Scirica BM, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis inmyocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011; 162(5):818-825.e6.
12. Scirica BM, Braunwald E, Raz I, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130(18):1579-1588.
13. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.
14. Mosenzon O, Bhatt DL, Litwak LE, et al Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2014;57(suppl 1):S84.
15. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A report of the American College of Cardiology/American Heart Association Task Force on clinical data standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). American College of Cardiology. http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2015/01/07/17/59/2014-acc-aha-key-dataelements-and-definitions. Accessed September 28, 2017.
16. Demler OV, Paynter NP, Cook NR. Tests of calibration and goodness-of-fit in the survival setting. Stat Med. 2015;34(10):1659-1680.
17. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3(2):143-152.
18. Pencina MJ, Steyerberg EW, D'Agostino RB Sr. Net reclassification index at event rate: Properties and relationships [published online July 18, 2016]. Stat Med.
19. Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176(6):473-481.
20. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med. 2015; 373(7):610-620.
21. Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: A secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(9): 989-998.
22. Standards of medical care in diabetes-2015: Summary of revisions. Diabetes Care. 2015; 38(suppl):S4.
23. Jackson CE, Solomon SD, Gerstein HC, et al; CHARM Investigators and Committees. Albuminuria in chronic heart failure: Prevalence and prognostic importance. Lancet. 2009;374(9689):543-550.
24. Masson S, Latini R, Milani V, et al; GISSI-HF Investigators. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: Data from the GISSI-Heart Failure trial. Circ Heart Fail. 2010;3(1):65-72.
25. Blecker S, Matsushita K, Köttgen A, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58(1):47-55.
26. Hockensmith ML, Estacio RO, Mehler P, et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail. 2004;10(2):126-131.
27. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P; DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care. 2003; 26(3):855-860.
28. Udell JA, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015; 38(4):696-705.
29. Astor BC, Matsushita K, Gansevoort RT, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease: A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79(12):1331-1340.
30. Gansevoort RT, Matsushita K, van der Velde M, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: A collaborativemeta-analysis of general and high-risk population cohorts. Kidney Int. 2011; 80(1):93-104.
31. Matsushita K, van der Velde M, Astor BC, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborativemeta-analysis. Lancet. 2010; 375(9731):2073-2081.
32. Waheed S, Matsushita K, Sang Y, et al. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2012;60(2):207-216.
33. Gori M, Gupta DK, Claggett B, et al. Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016;39(5):677-685.
34. Clodi M, Resl M, Neuhold S, et al. A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus. Eur J Prev Cardiol. 2012;19(5):944-951.
35. Olsen MH,Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: A LIFE substudy. J Hypertens. 2006;24(8):1531-1539.
36. Ruggenenti P, Porrini E, Motterlini N, et al; BENEDICT Study Investigators. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J AmSoc Nephrol. 2012;23(10):1717-1724.
37. Mori H, Okada Y, Arao T, Tanaka Y. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5(3): 313-319.
38. Barnett AH, Mithal A, Manassie J, et al; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369-384.
39. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4):311-322.